Navigation Links
Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
Date:12/12/2011

LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment of glioblastoma multiforme (GBM), the most common and aggressive brain tumor in humans. Regulus will apply its expertise in microRNA therapeutics to discover chemically modified oligonucleotide anti-miRs for testing at the Samsung Medical Center in preclinical models that mimic human brain cancer. Accelerate Brain Cancer Cure (ABC2), a non-profit organization dedicated to accelerating therapies for brain cancer patients, has awarded Regulus a grant to support the research.

 

"GBM is a devastating disease with limited treatment options," said Neil W. Gibson, Ph.D. Chief Scientific Officer of Regulus Therapeutics. "At Regulus, we have successfully targeted microRNAs in multiple disease settings and believe that targeting dysregulated microRNAs using chemically modified oligonucleotide anti-miRs provides a potential therapeutic approach for GBM."

 

"A major hurdle in the discovery and development of novel therapeutics for GBM has been the lack of relevant animal models," said Do Hyun Nam, Ph.D. Professor and Director of Institute for Refractory Cancer Research, Samsung Medical Center. "In our collaboration with Regulus, we will utilize a recently developed model in which tumors derived from human patients are transplanted into mice resulting in a model directly relevant to human disease."

 

"Regulus has an impressive track record of executing on innovation in the field of microRNA therapeutics," said Max Wallace, Chief Executive Officer, ABC2. "The combination of Regulus' expertise in microRNA therapeutics with Samsung's preclinical GBM models compelled us to support this pr
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
4. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
5. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and VANCOUVER, British Columbia , ... FSE: 20B OTCQB: BMKDF) -- The ultimate goal in ... that is capable of detecting tumors before they become ... the development of such an assay has been the ... and industry. Although many breakthrough diagnostics have been invented ...
(Date:3/4/2015)... März 2015 Unfors RaySafe, ... Bereich diagnostische Röntgenstrahlung, stellte heute auf ... European Congress of Radiology (ECR) in ... einen neuen Strahlungsüberwachungssensor vor. ... Der RaySafe X2-Überwachungssensor stellt ...
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
Breaking Medicine Technology:New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7
... its Footprint by Acquiring 33 Retail Pharmaceutical Stores -- LIUZHOU CITY, China, Sept. 27 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
... Inc ., (Nasdaq: OMCL ) a leading ... today announced Deaconess Health System,s selection of ... SecureVault™ controlled substance security system to improve ... across the health system network. Deaconess chose to replace ...
Cached Medicine Technology:China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 2China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 3China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 4China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 5China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 6China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 7China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores 8Deaconess Health System Selects Omnicell's Medication Management System for Product Reliability and Improved Patient Care 2Deaconess Health System Selects Omnicell's Medication Management System for Product Reliability and Improved Patient Care 3
(Date:3/5/2015)... Florida (PRWEB) March 05, 2015 ... organization which provides vascular, echocardiogram and NCV ... F.A.C.C. as the Chief Medical Officer. Dr. Artel will ... the development of the WimbledonMED program and the continued ... been passionate about working with Wimbledon Health Partners as ...
(Date:3/5/2015)... March 05, 2015 March 5, 2015 ... off next week (March 8-14, 2015), children’s hospitals around ... play in making hospital stays as safe as possible ... children’s hospitals—Children’s Hospitals’ Solutions for Patient Safety (SPS) and ... for families to follow when visiting the hospital with ...
(Date:3/5/2015)... March 05, 2015 The MTC 5-day ... to assist doctors, from a variety of dental disciplines, ... Shelly Akazany explains. "From the onset we wanted this ... doctors, and thanks to the excellence of the lecturers ... participants, it has more than satisfied our aims." ...
(Date:3/5/2015)... What makes a legend? In the case of renowned ... of exceptional courtroom performance, championing big causes and underdogs alike ... brilliant service, the Dallas Bar Association has named Schmidt a ... at a luncheon on Tuesday, April 7, 2015 at 12 ... nominees for this year are Bob Vial, Deborah Hankinson and ...
(Date:3/5/2015)... Lakeview Regional Medical Center is ... American Heart Association’s Heart Walk as the Signature Heart ... Executive Officer, is serving as Chairman of the event, ... at Fontainebleau State Park beginning at 9AM. In addition ... teams participating in this year’s event. Anyone is welcome ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2Health News:C.L. Mike Schmidt Named "Legend In Trial Law" by Dallas Bar Association 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 3
... Million in Compensation and Benefits, MINNEAPOLIS, Dec. 6 ... William McGuire, today agreed to,terms with the UnitedHealth Special ... than $420 million in stock options and other,compensation to ... during,his tenure as CEO of the company, in addition ...
... against colorectal, prostate and oral tumors , , THURSDAY, ... from black raspberries, a fruit beverage and old-fashioned ... to treat or prevent different types of cancer, ... not been considered good treatments for chronic illness, ...
... Inc. (NYSE: WPI ), a leading ... reached a settlement with Novartis,Pharmaceuticals Corporation, Novartis ... and Proterra AG (collectively,"Novartis") on outstanding patent ... (rivastigmine tartrate) capsules., Under the terms ...
... (Nasdaq: NBIX ) announced today that the ... Veralliance Properties for its real estate,assets. Total consideration ... Concurrently with the closing of the transaction, Neurocrine,leased ... term, with renewal,options. Neurocrine also has certain options ...
... EXEL ) announced today that that it will hold ... of Hematology,48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ... webcast and may be accessed in the Event Calendar,page under ... -- Michael Morrissey, PhD, President of Research & Development ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
Cached Medicine News:Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3Health News:Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation 2Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2
IDS Rapid SS/u, a microbial identification system....
Versatrek 240 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
ELP 40- 8 Way Head Strip Plate Washer....
The 96 PW is an intelligent full microplate washer with a 96 needle wash head washing all wells simultaneously. This instrument gives high throughput and outstanding washing efficiency....
Medicine Products: